

Drug Utilization Review Board Meeting

November 7, 2017

Therapeutic Class	Drug Name	Current PDL Status	DCH Decisions
Drug Reviews			
Dermatologics, Atopic Dermatitis			
	Dupixent (Subcutaneous) Injection	Non-PDL	NP/PA
Movement Disorder Drug Therapy			
	Ingrezza (Oral) Capsule	Non-PDL	NP/PA
Antivirals, Hepatitis C Direct-Acting Agents			
	Mavyret (Oral) Tablet	P/PA	P/PA
Gastrointestinal Agents, Chronic Idiopathic Constipation (CIC)			
	Trulance (Oral) Tablet	Non-PDL	NP/PA
Postmenopausal Osteoporosis, Parathyroid Hormone			
	Tymlos (Subcutaneous) Injection	Non-PDL	NP/PA
Bronchodilators, Anticholinergics			
	Utibron (Inhalation) Powder	Non-PDL	NP/PA
	Combivent (Inhalation) Solution	P	NP/PA

PDL=Preferred Drug List; P=preferred; NP=non-preferred; PA=prior authorization